Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Flow cytometry antibodies used.

Article Snippet: CD36-PEVio770 , Miltenyi , 130-110-742 , REA770 , .

Techniques: Flow Cytometry, In Vivo, In Vitro

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Murlentamab opsonization of SKOV3-R2 + orients naïve macrophages and reprograms TAMs towards an M1-like profile. SKOV3-R2 + ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). ( A ) The proportion of macrophages expressing M1/M2 membrane markers (CD32, CD64, CD80, TLR2, CD163, CD36 and CD206) was determined by flow cytometry after three days of co-culture with SKOV3-R2 + cells. ( B ) The release of cytokines (IL1β, IL12, TNFα, IL6, IFNγ, IL10) and chemokines (CCL2, CCL4, CCL5, CXCL9 and CXCL10) in the culture medium was determined by AlphaLISA after three days of co-culture with SKOV3-R2 + cells. Data shown (boxplots) are the results from three different experiments (performed with three different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.

Article Snippet: CD36-PEVio770 , Miltenyi , 130-110-742 , REA770 , .

Techniques: Labeling, Cell Culture, Derivative Assay, Expressing, Membrane, Flow Cytometry, Co-Culture Assay

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Anti-atherogenic effects of CD36-targeted epigallocatechin gallate-loaded nanoparticles

doi: 10.1016/j.jconrel.2019.04.018

Figure Lengend Snippet: The binding and uptake of NBD-labeled Vnano and L-Vnano by mouse peritoneal macrophages via their CD36 receptor. A, Mouse peritoneal macrophages were treated with non-targeted Vnano or targeted L-Vnano at 37°C; B, Mouse peritoneal macrophages were treated with Vnano or L-Vnano at 4°C; C, Mouse peritoneal macrophages were treated with red RPE-labeled anti-mouse CD36 antibody (λ of excitation is 496 nm, λ of emission is 578 nm) in combination with Vnano or L-Vnano at 4°C; D, Mouse peritoneal macrophages were transfected without CD36 siRNA (control) or with scramble siRNA (negative control) or with CD36 siRNA (CD36 knockdown). CD36 siRNA transfection decreased CD36 protein expression in mouse peritoneal macrophages; E, The binding and uptake of L-Vnano by control, CD36 negative control or CD36 knockdown mouse peritoneal macrophages. Bar length was 200 μm. NBD-labeled Vnano and L-Vnano were green (λ of excitation is 460 nm; λ of emission is 535 nm). Cell nuclei were stained by DAPI (λ of excitation is 358 nm, λ of emission is 461 nm) (blue color). Images were representatives of three independent experiments.

Article Snippet: Moreover, for competitive binding assay with mouse CD36 antibody, mouse peritoneal macrophages were treated with RPE-labeled anti-CD36 antibody (MCA2748PE, AbD Serotec, Raleigh, NC, USA) in combination with NBD-labeled Vnano or L-Vnano at 4°C for 2 hours.

Techniques: Binding Assay, Labeling, Transfection, Negative Control, Expressing, Staining

Journal: Cell

Article Title: A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

doi: 10.1016/j.cell.2022.01.012

Figure Lengend Snippet:

Article Snippet: CD36 (5-271)-155Gd , Fluidigm , Cat# 3155012B, RRID: AB_2756286.

Techniques: Mass Cytometry, Flow Cytometry, Recombinant, Staining, Selection, Antibody Labeling, Labeling, Isolation, Sample Prep, Luminex, Quantitative Proteomics, Generated, Gene Expression, Clone Assay, Marker, Expressing, Mass Spectrometry, Derivative Assay, RNA Sequencing, Sequencing, Illumina Sequencing, Software, Variant Assay

Journal: Cell reports

Article Title: Neutral ceramidase-dependent regulation of macrophage metabolism directs intestinal immune homeostasis and controls enteric infection

doi: 10.1016/j.celrep.2022.110560

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: CD36 (147 Sm) , Fluidigm , Cat# 3147018B;RRID:N/A.

Techniques: Recombinant, Western Blot, Protease Inhibitor, Enzyme-linked Immunosorbent Assay, SYBR Green Assay, Cell Culture, IP Phosphatase Assay, Software

Journal: Respiratory Research

Article Title: An investigation of the resolution of inflammation (catabasis) in COPD

doi: 10.1186/1465-9921-13-101

Figure Lengend Snippet: Representative examples of different macrophage immunostaining intensities (absent/moderate vs. intense staining) for CD44, CD36, VEGF and TGFβ. For further explanations, see text.

Article Snippet: Formalin-fixed paraffin-embebbed tissue sections (3 μm thick) were immunostained with the following monoclonal mouse antibodies: anti-human CD44, Phagocytic Glycoprotein-1, clone DF1485 (Dako, Glostrup, Denmark); anti-human VEGF, clone VG1 (Dako, Glostrup, Denmark); anti-human TGFbeta (AbDSerotec, Oxford, UK); anti-human CD36, clone SMO, (AbDSerotec, Oxford, UK).

Techniques: Immunostaining, Staining

Journal: Respiratory Research

Article Title: An investigation of the resolution of inflammation (catabasis) in COPD

doi: 10.1186/1465-9921-13-101

Figure Lengend Snippet: Individual and mean (bars) values of the proportion of macrophages with intense staining for CD44 , CD36, VEGF and TGFβ in patients with COPD, smokers with normal spirometry and non-smokers. (S = current smokers; EX-S = former smokers; NS = non-smokers). For further explanations, see text.

Article Snippet: Formalin-fixed paraffin-embebbed tissue sections (3 μm thick) were immunostained with the following monoclonal mouse antibodies: anti-human CD44, Phagocytic Glycoprotein-1, clone DF1485 (Dako, Glostrup, Denmark); anti-human VEGF, clone VG1 (Dako, Glostrup, Denmark); anti-human TGFbeta (AbDSerotec, Oxford, UK); anti-human CD36, clone SMO, (AbDSerotec, Oxford, UK).

Techniques: Staining

Journal: Scientific Reports

Article Title: Endothelial Cell Phenotypes are Maintained During Angiogenesis in Cultured Microvascular Networks

doi: 10.1038/s41598-018-24081-z

Figure Lengend Snippet: Illustration of CD36 labeling in ex vivo cultured microvascular networks and stimulated in vivo microvasculature. Comparison between Day 3 ( Ex Vivo ) ( A–C ) and Day 3 ( In Vivo ) ( D–F ) microvascular networks revealed diminishing CD36 labeling along the length of the capillary sprout becoming absent at the tip. Arrows identify examples of CD36-negative capillary sprouts. Scale bars = 200 µm. ( G , H ) Capillary sprouts exhibited a substantial decrease in CD36 labeling compared to larger network vessels ( > 10 µm) in Day 3 ( Ex Vivo ) and Day 3 ( In Vivo ) tissues. White and black bars represent “Sprouts” and “Networks” respectively for Day 3 ( Ex Vivo ) and Day 3 ( In Vivo ) groups. The *** indicates a significant difference of p < 0.001 by Mann-Whitney U test.

Article Snippet: The following primary antibodies were used: UNC5b (1:100; Abcam; Cambridge, MA), VEGFR-2 (1:50; Santa Cruz Biotechnology; Dallas, TX), Alexa-568 Phalloidin (1:50; Invitrogen; Carlsbad, CA), CD36 (1:100; Novus Biologicals; Littleton, CO), and PECAM (1:200; BD Pharmingen; San Jose, CA).

Techniques: Labeling, Ex Vivo, Cell Culture, In Vivo, Comparison, MANN-WHITNEY